U.S. Markets closed

Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 7.3%

Zacks Equity Research

Amicus Therapeutics, Inc. FOLD was a big mover last session, as the company saw its shares rise over 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 24.6% in the past one-month time frame.

The company has seen one upward estimate revision in the past 30 days. However, the Zacks Consensus Estimate for the current quarter has remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future

Amicus Therapeuticshas a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Amicus Therapeutics, Inc. Price

Amicus Therapeutics, Inc. Price | Amicus Therapeutics, Inc. Quote

A better-ranked stock in the Medical - Biomedical and Geneticsindustry is VIVUS, Inc. (VVUS), which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is FOLD going up? Or down? Predict to see what others think: Up or Down

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

 Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

 See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Click for Free Amicus Therapeutics, Inc. (FOLD) Stock Analysis Report >>
 
To read this article on Zacks.com click here.
 
Zacks Investment Research